Research location
Baoji
Shanxi, China
Advertisement
Research activity in Baoji
Shanxi, ChinaCureCurrent currently publishes aggregate city-level research activity for this location: 9 trials and 9 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Baoji
9 linked trials · page 1 of 1Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary DiseaseNCT07464587 · 2026-04-14 · 1 site observation
RECRUITING
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary DiseaseNCT07147946 · 2025-09-01 · 1 site observation
NOT_YET_RECRUITING
The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).NCT06606509 · 2024-11-07 · 1 site observation
NOT_YET_RECRUITING
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast CancerNCT06561607 · 2024-10-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerNCT05042375 · 2022-09-08 · 1 site observation
UNKNOWN
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung CancerNCT05353257 · 2022-05-17 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)NCT04325763 · 2020-05-27 · 1 site observation
UNKNOWN
A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLCNCT03668496 · 2018-11-09 · 1 site observation
UNKNOWN
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung AdenocarcinomaNCT02103257 · 2014-03-01 · 1 site observation
UNKNOWN
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.